ClinicaliQ Trial Snapshot
- A Study of Zasocitinib (TAK-279) in Adults With Active Crohn’s Disease — Recruiting • Phase II • Rheumatology • NCT07403968.
- What is being tested: Zasocitinib (TAK-279), an investigational therapy targeting cellular and molecular mechanisms of inflammation, is being evaluated for its efficacy in treating active Crohn's disease in adult patients.
- Patient eligibility overview: The trial enrolls adults with confirmed active Crohn's disease; specific eligibility criteria typically include disease activity markers, previous treatment history, and baseline inflammatory parameters, though full detailed criteria would be specified in the complete protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Crohn's disease (CD) is a serious, long-term condition that can cause swelling (inflammation) and painful ulcers anywhere in the gut. This study will investigate whether zasocitinib can improve CD biology at the cellular and molecular level in adults. The main aims of this study are to better understand zasocitinib's mechanism of action in CD and evaluate how safe this treatment is. The participants will be treated with zasocitinib for 3 months (12 weeks) and will need to undergo a test where a doctor uses a thin, flexible tube with a…
Eligibility Snapshot
- : 1. Men and women aged 18 to 75 years can participate in the study. 2. Must have been diagnosed with Crohn's disease (CD) at least 1 month (30 days) before study start. 3. Must have received other treatments for CD earlier but no longer tolerate these treatments or the treatment no longer helps.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.